Juvenile polymyositis

Summary

Juvenile polymyositis (MONDO:0019734) is a disease and 2 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous. A subtype of juvenile idiopathic inflammatory myopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	juvenile polymyositis
Mondo ID	MONDO:0019734
EFO	EFO:1001988
Orphanet	93568
ICD-11	633330307
NCIT	C114358
SNOMED CT	738526005
UMLS	C3826988
MedGen	819736
GARD	0012742
Is cancer (heuristic)	no

Also known as: JPM · juvenile PM

Disease family

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › acquired skeletal muscle disease › acquired idiopathic inflammatory myopathy › juvenile idiopathic inflammatory myopathy › juvenile polymyositis

Related subtypes (2): juvenile dermatomyositis, juvenile overlap myositis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06154252	PHASE2/PHASE3	RECRUITING	RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT01276470	Not specified	RECRUITING	Environmental Risk Factors for the Anti-synthetase Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	1